Wire · opportunities
BMS' RYZ101 meets Phase III endpoint in landmark alpha-radiopharmaceutical trial
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 13 October 2026 · Fusion42 review
Bristol Myers Squibb's RYZ101, an alpha-emitting targeted radiopharmaceutical therapy, met its primary endpoint in Phase III ACTION-1 trial showing significant progression-free survival improvement in patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors after lutetium-177 therapy. This success sets RYZ101 up for FDA regulatory submission discussions, offering a new treatment option where no prior randomized Phase III evidence existed.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 12 Oct 2026 and 13 Oct 2026.
◆ ◆ The Wire takeaway
Your biotech venture must now factor in alpha-radiopharmaceuticals as a new regulatory frontier in neuroendocrine tumour treatments. The FDA's likely fast track on RYZ101 opens a window to challenge beta-emitters and address a patient group previously lacking Phase III-validated options.
◆ Coverage
2 sources · first reported 12 Oct 2026 · latest 13 Oct 2026
◆ Related on Wire
◆ Topics